Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders.
Abeya A LotfiAsmaa E MohamedNahela A ShalabyDeena S EissaEhab El-DabaaAyman M SallamMahmoud M KamelHisham AbdelazizAmal M El-AfifiAhmed S Abdel-MoneimPublished in: International journal of immunopathology and pharmacology (2021)
Despite the link between HCV and malignant lymphoproliferative disorders has been established, the association between occult hepatitis C virus infection and malignant lymphoproliferative disorders remains obscure. The present study intended to identify the possible association between occult HCV infection and malignant lymphoproliferative disorders. Newly diagnosed patients with LPDs were screened for the presence of HCV-RNA in both plasma and PBMCs. PBMCs of the subjects were also, examined by transmission and immuno-electron microscopy. LPD patients showed a high percentage of HCV infection (71.9%): OCI-HCV (37.5%) and HCV (34.38%). Meanwhile, 28.13% of LPD patients did not show any evidence of HCV infection. Ultrastructural examination of PBMCs revealed the presence of intracytoplasmic vacuoles enclosing viral like particles, which were less prominent in occult HCV patients. The possibility of occult HCV should be considered in patients with LPDs which can be helpful in the management of the treatment protocol in order to set up a balance between the control of the tumor progression and minimizing post chemotherapy complications related to HCV infection.
Keyphrases
- hepatitis c virus
- newly diagnosed
- end stage renal disease
- human immunodeficiency virus
- ejection fraction
- epstein barr virus
- peritoneal dialysis
- hepatitis c virus infection
- prognostic factors
- randomized controlled trial
- sars cov
- squamous cell carcinoma
- electron microscopy
- radiation therapy
- risk factors
- single cell
- rectal cancer
- combination therapy